CSR

Governance

governance that meets the approval of many different types of stakeholders

Board of Directors

BOD Composition (As of 2021.06.30)
Board of Directors
Category Name Responsibilities Election date Term expiry date
Executive Director Jong-Soo Woo Business Management 2016.03.18 2022.03.15
Se-Chang Kwon New Drug R&D 2017.03.10 2023.03.20
Chong-Yoon Lim Business Development 2018.03.16 2024.03.26
Jong-Hoon Lim Management Planning /CIO 2017.03.10 2023.03.20
Gwan-Sun Lee Global Strategy 2016.03.18 2022.03.15
Non-executive Director Dong-Ho Lee Non-executive Director 2016.03.18 2022.03.15
Sung-Hoon Kim Non-executive Director 2016.03.18 2022.03.15
Dong-Cheol Suh Non-executive Director 2017.03.10 2023.03.20
2021 BOD Meetings
2021 BOD Meetings
Held On Main resolution matters
Feb. 04, 2021

Report on the 2020 closing

Mar. 09, 2021

Convening the 11th Regular Shareholders’ General Meeting and setting the agenda

Cash dividends

CEO’s presentation on the operational status of the internal accounting management system

Audit Committee’s report on evaluation of the operational status of the internal accounting management system

Mar. 23, 2021

Approval of the financial 2020 statements

Apr. 27, 2021

Report on 1Q settlement of accounts

2020 BOD Meetings
2020 BOD Meetings
Held On Main resolution matters
Feb. 07, 2020

Report on the 2019 closing

Mar. 04, 2020

Convening the 10th Regular Shareholders’ General Meeting and setting the agenda

Cash dividends

Mar. 06, 2020

Adding the agenda for 11th Regular Shareholders’ General Meeting

Mar. 16. 2020

Approval of the financial 2019 statements

Mar. 20, 2020

Appointment of CEO

Apr. 28, 2020

Report on 1Q settlement of accounts

Establishment of Hanmi pharm. code of Ethic

July. 29, 2020

Report on 2Q settlement of accounts

Oct. 30, 2020

Report on 3Q settlement of accounts

Dec. 15, 2020

Capitalization of reserve